Publications

human papillomavirus-16/18 as04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy chinese women from hong kong.

to assess the immunogenicity and safety of human papillomavirus-16/18 as04-adjuvanted cervical cancer vaccine in chinese women aged 18 to 35 years enrolled from hong kong.